Management of Bone Disease in Gaucher Disease Type 1: Clinical Practice
Open Access
- 17 December 2014
- journal article
- review article
- Published by Springer Nature in Advances in Therapy
- Vol. 31 (12) , 1197-1212
Abstract
Gaucher disease is a rare autosomal recessive disorder of glycosphingolipid metabolism resulting from deficient activity of the lysosomal enzyme beta-glucocerebrosidase that causes accumulation of glucosylceramide in tissue macrophage with damage to hematological, visceral, and skeletal organ systems. Severity and progression may vary independently among these domains, necessitating individualized therapy. Skeletal involvement is highly prevalent and often associated with intense pain, impaired mobility, and reduced quality of life. Enzyme replacement therapy improves parameters in all affected domains, but skeletal involvement requires longer treatment and higher dosages to obtain significant results. Despite numerous papers on bone complications in patients with Gaucher disease, there are no specific indications on how to assess properly bone involvement in such condition, the frequency of assessment, the use of markers for osteoblast and osteoclast activity, or the administration of bisphosphonates or other symptomatic drugs in adult and pediatric patients. Starting from a re-evaluation of cases with bone involvement, we have identified some common errors in the diagnostic approach and management. The aim of this paper was to propose a methodological and critical approach to the diagnosis, follow-up and treatment of bone disease in patients with Gaucher disease type 1.Keywords
This publication has 65 references indexed in Scilit:
- Bone Turnover Markers in Patients with Type 1 Gaucher DiseaseHematology Reports, 2012
- Long‐term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatmentJournal of Inherited Metabolic Disease, 2012
- Osteopenia in Gaucher disease develops early in life: Response to imiglucerase enzyme therapy in children, adolescents and adultsBlood Cells, Molecules, and Diseases, 2011
- Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 studyBlood, 2010
- A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1Blood, 2010
- Bone events and evolution of biologic markers in Gaucher disease before and during treatmentArthritis Research & Therapy, 2010
- Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosisBritish Journal of Haematology, 2009
- A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme—A Preclinical and Phase I InvestigationPLOS ONE, 2009
- Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48‐month longitudinal cohort studyClinical Genetics, 2008
- Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher diseaseSkeletal Radiology, 2008